Prescient Therapeutics Ltd

ASX:PTX ISIN:AU000000PTX3

Prescient Therapeutics Limited is a clinical-stage oncology company. The Company's principal activities include in-licensing of intellectual property; the preparation for and conduct of clinical trials relating to the Company's products; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. 
 
           

查看其它语言版本

新闻

2011年2月14日澳洲股市:Black Fire Minerals (ASX:BFE)将收购美国钨/铜项目

🕔2/14/2011 12:20:00 PM 17783

2011年2月14日澳洲股市报告包括:Black Fire Minerals (ASX:BFE)将收购美国内华达州已开发的Pilot Mountain钨-铜项目的100%股份;Virax Holdings Limited (ASX:VHL)将开发一种皮肤癌新药;Southern Cross Goldfields Limited (ASX:SXG)在西澳发现近地表高品位金矿;Prosperity Resources Limited (ASX:PSP)在印尼开始钻探。

阅读全文
###

134,715 公司背景浏览

  • 本页浏览人次: (过去7日: 6) (过去30日: 48) (自发布以来: 11786) 

公司详细信息

    传真
  • (03) 9853 5134 
  • 主要部门
  • 医疗-制药 
  • 支柱产业
  • 生物科技 
  • 主页
  • www.virax.com.au/

更多新闻纪录

  • 2024/12/17: Appointment of Chief Executive Officer*
  • 2024/12/11: Change of Director's Interest Notice*
  • 2024/12/11: Notification regarding unquoted securities - PTX*
  • 2024/12/04: Change of Director's Interest Notices x4*
  • 2024/12/04: Notification of cessation of securities - PTX*
  • 2024/11/14: Results of Annual General Meeting*
  • 2024/11/14: Chair and CEO AGM Presentation*
  • 2024/10/31: September 2024 Quarterly Update and Appendix 4C*
  • 2024/10/14: Notice of Annual General Meeting/Proxy Form*
  • 2024/10/03: Change of Director's Interest Notice*
*refer to company website